Related Experiment Video
Updated: Oct 6, 2025
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
Published on: October 25, 2024
Intra-trial Mean 25(OH)D and PTH Levels and Risk of Falling in Older Men and Women in the Boston STOP IT Trial
Bess Dawson-Hughes1, Jifan Wang1, Kathryn Barger1
1Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA, USA.
Context:
Supplementation with vitamin D has the potential to both reduce and increase risk of falling, and parathyroid hormone (PTH) may contribute to fall risk.
Objective:
To assess the associations of intra-trial mean circulating levels of 25-hydroxyvitamin D [25(OH)D] and PTH on incident falls in healthy older adults.
Design:
Observational within a clinical trial.
Setting:
The Bone Metabolism Laboratory at the USDA Nutrition Center at Tufts University.
Participants:
410 men and women age ≥65 years who participated in the 3-year Boston STOP IT trial to determine the effect of supplementation with 700 IU of vitamin D3 plus calcium on incident falls (secondary endpoint). Intra-trial exposures of 25(OH)D and PTH were calculated as the mean of biannual measures up to and including the first fall.
Main Outcome Measures:
Incidence of first fall.
Results:
Intra-trial mean 25(OH)D was significantly associated with risk of falling in a U-shaped pattern; the range associated with minimal risk of falling was approximately 20 to 40 ng/mL. PTH was not significantly associated with risk of falling.
Conclusions:
The findings highlight the importance of maintaining the circulating 25(OH)D level between 20 and 40 ng/mL, the range that is also recommended for bone health. At PTH levels within the normal range, there was no detectible independent association of PTH with fall risk.
More Related Videos
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:11Clinical Trials: Overview